The common statin drug Simvastatin reduces brain atrophy and slows the progression of secondary progressive multiple sclerosis (SPMS). The effects appear to be independent of the drug's cholesterol-lowering effects.
Researchers report statins could potentially reduce cardiovascular risks in people with Friedreich's ataxia.
Study reveals statins are associated with a reduced risk of Alzheimer's disease, but the reduction of risk varied by race, ethnicity and statin type.
A clinical trial is being conducted to assess the effectiveness of a cholesterol lowering drug in the treatment of Parkinson's disease.
